Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

DelMar Reveals Plan for China Trial of Lung Cancer Drug

publication date: Sep 9, 2015
DelMar Pharma, a Vancouver-Menlo Park, CA company, together with its China partner, Guangxi Wuzhou Pharma, announced plans to start a China Phase IV trial of VAL-083 in patients with refractory and relapsed non-small cell lung cancer. The drug is already approved for NSCLC in China, but most patients are prescribed newer tyrosine kinase inhibitors. Based on preclinical studies, DelMar believes VAL-083 is effective against TKI-resistant NSCLC, which the trial is designed to prove. More details....

Stock Symbol: (OTCQX: DMPI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital